TY - JOUR
T1 - Novel Immune Cell Subsets Exhibit Different Associations With Vascular Outcomes in Chronic Kidney Disease Patients—Identifying Potential Biomarkers
AU - Rodríguez-Carrio, Javier
AU - Carrillo-López, Natalia
AU - Ulloa, Catalina
AU - Martín-Carro, Beatriz
AU - Rodríguez-Suárez, Carmen
AU - Naves-Díaz, Manuel
AU - Sánchez-Álvarez, Emilio
AU - Rodríguez-García, Minerva
AU - Arcidiacono, Maria Vittoria
AU - Fernández-Mariño, Belinda
AU - Cannata-Andía, Jorge B.
AU - Suárez, Ana
AU - Dusso, Adriana S.
N1 - Funding Information:
This work was supported by European Union FEDER funds, Fondo de Investigación Sanitaria (PI14/01452, PI16/00113, PI17/02181, PI19/00532) from Instituto de Salud Carlos III (ISCIII), Plan de Ciencia, Tecnología e Innovación 2013-2017 del Principado de Asturias (GRUPIN14-028 and IDI/2018/000152) from Fundación para el Fomento en Asturias de la Investigación Científica Aplicada y la Tecnología (FICYT), Red de Investigación Renal-RedInREN (RETIC REDINREN RD16/0009) from ISCIII, and by Sociedad Asturiana Fomento Investigaciones Metabólicas (SAFIM). JR-C is supported by postdoctoral contracts from the Juan de la Cierva (IJCI-2017-32070, Ministerio de Ciencia e Innovación, Spain) and Sara Borrell programs (CD19/00120, from ISCIII). NC-L is supported by GRUPIN14-028 and IDI/2018/000152, and AD is supported by Asociación Investigación de Fisiología Aplicada and ISPA. BM-C was supported by ISCIII-ISPA (PI17/00384) and by
Funding Information:
Funding. This work was supported by European Union FEDER funds, Fondo de Investigaci?n Sanitaria (PI14/01452, PI16/00113, PI17/02181, PI19/00532) from Instituto de Salud Carlos III (ISCIII), Plan de Ciencia, Tecnolog?a e Innovaci?n 2013-2017 del Principado de Asturias (GRUPIN14-028 and IDI/2018/000152) from Fundaci?n para el Fomento en Asturias de la Investigaci?n Cient?fica Aplicada y la Tecnolog?a (FICYT), Red de Investigaci?n Renal-RedInREN (RETIC REDINREN RD16/0009) from ISCIII, and by Sociedad Asturiana Fomento Investigaciones Metab?licas (SAFIM). JR-C is supported by postdoctoral contracts from the Juan de la Cierva (IJCI-2017-32070, Ministerio de Ciencia e Innovaci?n, Spain) and Sara Borrell programs (CD19/00120, from ISCIII). NC-L is supported by GRUPIN14-028 and IDI/2018/000152, and AD is supported by Asociaci?n Investigaci?n de Fisiolog?a Aplicada and ISPA. BM-C was supported by ISCIII-ISPA (PI17/00384) and by a graduate fellowship from the Gobierno del Principado de Asturias (Severo Ochoa program BP19-057).
Publisher Copyright:
© Copyright © 2021 Rodríguez-Carrio, Carrillo-López, Ulloa, Martín-Carro, Rodríguez-Suárez, Naves-Díaz, Sánchez-Álvarez, Rodríguez-García, Arcidiacono, Fernández-Mariño, Cannata-Andía, Suárez and Dusso.
PY - 2021/5/25
Y1 - 2021/5/25
N2 - Background and Aims: Alterations in novel immune cell subsets, such as angiogenic T cells (Tang), senescent T cells (CD4+CD28null), and monocyte subsets are associated with impaired vascular homeostasis in several inflammatory conditions. However, mediators underlying vascular deterioration in chronic kidney disease (CKD) are poorly characterized. This study assessed their role in the vascular deterioration of CKD using a broad spectrum of surrogate markers ranging from altered functionality to overt calcification. Methods: Tang (CD3+CD31+CXCR4+), CD4+CD28null cells, and monocytes [CD14/CD16 subsets and angiotensin-converting enzyme (ACE) expression] were measured in peripheral blood by flow cytometry in 33 CKD stage 5 patients undergoing peritoneal dialysis (CKD5-PD) and 15 healthy controls (HCs). Analyses were replicated in a hemodialysis cohort. Vascular surrogate markers (including adventitial vasa vasorum, pulse wave velocity, intima-media thickness, and vascular calcification) were assessed by appropriate imaging methods. Results: In CKD5-PD, decreased Tang levels (p < 0.001) were unrelated to clinical features or traditional cardiovascular (CV) risk factors but correlated negatively with troponin T levels (r = −0.550, p = 0.003). Instead, CD4+CD28null frequency was increased (p < 0.001), especially in those with vascular calcifications. Quantitative and qualitative differences were also observed within the monocyte pool, a shift toward CD16+ subsets and ACE expression being found in CKD. Equivalent results were observed in the replication cohort. Each subset associated distinctly with adverse vascular outcomes in univariate and multivariate analyses: while Tang depletion was linked to poor vascular function and subclinical atherosclerosis, increases in CD4+CD28null were associated with overt vascular thickening and calcification. Monocytes were not independently associated with vascular outcomes in CKD patients. Conclusions: Novel T cell and monocyte subsets are altered in CKD. Altered T-cell subpopulations, but not monocytes, exhibited distinct associations with different vascular outcomes in CKD. Tang are emerging biomarkers of subclinical vascular deterioration in CKD.
AB - Background and Aims: Alterations in novel immune cell subsets, such as angiogenic T cells (Tang), senescent T cells (CD4+CD28null), and monocyte subsets are associated with impaired vascular homeostasis in several inflammatory conditions. However, mediators underlying vascular deterioration in chronic kidney disease (CKD) are poorly characterized. This study assessed their role in the vascular deterioration of CKD using a broad spectrum of surrogate markers ranging from altered functionality to overt calcification. Methods: Tang (CD3+CD31+CXCR4+), CD4+CD28null cells, and monocytes [CD14/CD16 subsets and angiotensin-converting enzyme (ACE) expression] were measured in peripheral blood by flow cytometry in 33 CKD stage 5 patients undergoing peritoneal dialysis (CKD5-PD) and 15 healthy controls (HCs). Analyses were replicated in a hemodialysis cohort. Vascular surrogate markers (including adventitial vasa vasorum, pulse wave velocity, intima-media thickness, and vascular calcification) were assessed by appropriate imaging methods. Results: In CKD5-PD, decreased Tang levels (p < 0.001) were unrelated to clinical features or traditional cardiovascular (CV) risk factors but correlated negatively with troponin T levels (r = −0.550, p = 0.003). Instead, CD4+CD28null frequency was increased (p < 0.001), especially in those with vascular calcifications. Quantitative and qualitative differences were also observed within the monocyte pool, a shift toward CD16+ subsets and ACE expression being found in CKD. Equivalent results were observed in the replication cohort. Each subset associated distinctly with adverse vascular outcomes in univariate and multivariate analyses: while Tang depletion was linked to poor vascular function and subclinical atherosclerosis, increases in CD4+CD28null were associated with overt vascular thickening and calcification. Monocytes were not independently associated with vascular outcomes in CKD patients. Conclusions: Novel T cell and monocyte subsets are altered in CKD. Altered T-cell subpopulations, but not monocytes, exhibited distinct associations with different vascular outcomes in CKD. Tang are emerging biomarkers of subclinical vascular deterioration in CKD.
KW - CKD
KW - atherosclerosis
KW - inflammation
KW - vasa vasorum
KW - vascular outcomes
UR - http://www.scopus.com/inward/record.url?scp=85107429956&partnerID=8YFLogxK
U2 - 10.3389/fmed.2021.618286
DO - 10.3389/fmed.2021.618286
M3 - Article
C2 - 34113627
AN - SCOPUS:85107429956
SN - 2296-858X
VL - 8
JO - Frontiers in Medicine
JF - Frontiers in Medicine
M1 - 618286
ER -